What is the 13F Pro Quality Score for ELV?

13F Pro ranks Elevance Health, Inc. (ELV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ELV's current score at https://13fpro.ai/research/ELV (free sign-up required for the full ranking).

Which hedge funds own the most ELV stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ELV include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ELV as soon as new 13F filings post.

Where does 13F Pro source ELV data?

All Elevance Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Elevance Health, Inc. files with the SEC under CIK 1156039. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ELV in?

Elevance Health, Inc. (ELV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ELV research updated on 13F Pro?

ELV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Elevance Health, Inc.(ELV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1156039 ELV stock profile & AI dashboard →

13F Pro Quality Score

59.4/100

Rank #913 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

47.6/100

Profitability

44.4/100

Balance Sheet

63.2/100

Earnings Quality

30.0/100

Free Cash Flow

45.8/100

Institutional Flow

77.4/100

Revenue Scale

99.5/100

Dilution Risk

87.6/100

ELV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Elevance Health, Inc. (ELV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ELV at 59.4/100 on a 32-signal composite quality model, placing it at rank #913 of 2,879 stocks — the top half of the AI-ranked universe. ELV scores in the top quartile across revenue scale (99.5), institutional flow (77.4). Areas of concern include earnings quality (30.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Elevance Health, Inc. reports quarterly revenue of $50.5B, net income of $1.5B, an operating margin of 3.5%. Top institutional holders of ELV by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ELV trades on the NYSE exchange and files with the SEC under CIK 1156039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ELV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Elevance Health, Inc. directly from SEC EDGAR. Elevance Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 66 since 2022, currently 59.4 — a stable long-term trajectory across 53 quarterly and live scoring snapshots.

Revenue

Q2 2026

$50.5B

Net Income

Q2 2026

$1.5B

Free Cash Flow

Q2 2026

$1.6B

Operating Margin

Q2 2026

3.5%

ROIC

Q2 2026

2.3%

D/E Ratio

Q2 2026

0.70

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+12.5% YoY

$199.13BFY 2025

FY17 $90.04BFY22 $156.59BFY24 $177.01BFY25 $199.13B

Net Income

-5.3% YoY

$5.66BFY 2025

FY17 $3.84BFY22 $5.89BFY24 $5.98BFY25 $5.66B

Operating Income

-8.4% YoY

$7.20BFY 2025

FY17 $4.17BFY22 $8.28BFY24 $7.86BFY25 $7.20B

EPS (Diluted)

-1.8% YoY

$25.21FY 2025

FY17 $14.35FY22 $24.28FY24 $25.68FY25 $25.21

Total Assets

+3.9% YoY

$121.49BFY 2025

FY17 $70.54BFY22 $102.75BFY24 $116.89BFY25 $121.49B

Total Debt

+0.8% YoY

$33.15BFY 2025

FY17 $21.21BFY22 $25.61BFY24 $32.88BFY25 $33.15B

Op. Cash Flow

-26.1% YoY

$4.29BFY 2025

FY17 $4.18BFY22 $8.40BFY24 $5.81BFY25 $4.29B

Metric	FY 2025	FY 2024	FY 2022	FY 2017	FY 2016	FY 2015
Revenue	$199.13B +12.5%	$177.01B +13.0%	$156.59B +73.9%	$90.04B +6.1%	$84.86B +7.2%	$79.16B
Net Income	$5.66B -5.3%	$5.98B +1.5%	$5.89B +53.4%	$3.84B +55.6%	$2.47B -3.5%	$2.56B
Operating Income	$7.20B -8.4%	$7.86B -5.1%	$8.28B +98.4%	$4.17B -13.0%	$4.80B +1.0%	$4.75B
EPS (Diluted)	$25.21 -1.8%	$25.68 +5.8%	$24.28 +69.2%	$14.35 +55.8%	$9.21 -1.8%	$9.38
Total Assets	$121.49B +3.9%	$116.89B +13.8%	$102.75B +45.7%	$70.54B +8.4%	$65.08B +5.5%	$61.72B
Total Debt	$33.15B +0.8%	$32.88B +28.4%	$25.61B +20.8%	$21.21B +27.3%	$16.66B +5.0%	$15.86B
Operating Cash Flow	$4.29B -26.1%	$5.81B -30.8%	$8.40B +100.7%	$4.18B +28.0%	$3.27B -22.4%	$4.21B

AI Insight: ELV Financial Trends

Revenue volatility and operating cash flow collapse in Q4 2025 signal operational stress despite modest Q2 2026 recovery.

• Revenue swung from $49.7B (Q2 2025) to $41.8B (Q3 2025), then recovered to $49.7B (Q4 2025), before declining again to $41.3B (Q2 2026).

• Operating cash flow collapsed to $84M in Q4 2025 from $2.1B in Q2 2025, though rebounded to $4.3B in Q1 2026.

• Operating margin deteriorated from 4.9% (Q1 2026) to 4.3% (Q2 2026); Q4 2025 saw margin contract to 0.6%.

⚠ Debt increased from $27.1B (Q3 2024) to $33.1B (Q4 2025); leverage ratio elevated despite stable equity base of ~$44B.

⚠ Net income volatility persists—Q4 2025 fell to $547M from $1.7B in Q2 2025; pattern suggests underlying margin pressure.

AI Insight: ELV Ratio Trends

Elevance recovered from a severe Q4 2025 collapse, but profitability remains well below 2025 peak levels and ROIC has halved.

• Operating margin rebounded to 4.3% in Q2 2026 from 0.6% in Q4 2025, signaling operational stabilization post-crisis.

• ROIC remains depressed at 9.2% in Q2 2026 versus 17.5% in Q1 2025 peak; structural profitability challenge persists.

• Leverage drifted higher to 0.76 D/E in Q4 2025 before moderating to 0.70 in Q2 2026; balance sheet stabilizing.

⚠ Q4 sequential weakness pattern repeating: OpMargin, NPM, ROE all collapsed in Q4 2024 and Q4 2025. Investigate seasonality.

⚠ ROE down to 13.0% in Q2 2026 from 20.5% in Q1 2025; shareholder returns under pressure despite recent stabilization.

Get alerted when ELV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Elevance Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ELV

BlackRock, Inc.
$5.8B19,887,111 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.2B14,345,459 sh
STATE STREET CORP
$3.0B10,288,696 sh
WELLINGTON MANAGEMENT GROUP LLP
$2.4B8,228,537 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.9B6,356,077 sh
Sanders Capital, LLC
$1.7B5,894,303 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.5B5,192,707 sh
Artisan Partners Limited Partnership
$1.5B5,127,175 sh
Invesco Ltd.
$1.4B4,817,410 sh
HARRIS ASSOCIATES L P
$1.4B4,796,526 sh

Fund	Value	Shares
BlackRock, Inc.	$5.8B	19,887,111
VANGUARD CAPITAL MANAGEMENT LLC	$4.2B	14,345,459
STATE STREET CORP	$3.0B	10,288,696
WELLINGTON MANAGEMENT GROUP LLP	$2.4B	8,228,537
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.9B	6,356,077
Sanders Capital, LLC	$1.7B	5,894,303
GEODE CAPITAL MANAGEMENT, LLC	$1.5B	5,192,707
Artisan Partners Limited Partnership	$1.5B	5,127,175
Invesco Ltd.	$1.4B	4,817,410
HARRIS ASSOCIATES L P	$1.4B	4,796,526

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ELV on your watchlist

Track score changes the day Elevance Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ELV a good stock to buy?

13F Pro's AI-powered analysis of Elevance Health, Inc. (ELV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ELV are available on the ELV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ELV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ELV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Elevance Health, Inc.'s investment landscape.